Current Oral Health Reports

, Volume 5, Issue 1, pp 1–6 | Cite as

Periodontal Diseases/Treatment and Bisphosphonates

  • Pınar MeriçEmail author
  • Önder Gürlek
Systemic Diseases (N Buduneli, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Systemic Diseases


Purpose of Review

Host response against bacteria or their toxins eventually play a major role in alveolar bone destruction observed in periodontitis. Because of the role in bone resorption, bisphosphonates were applied as adjunct to non-surgical therapy. This review highlights the effects of bisphosphonates on clinical parameters as adjunct to periodontal treatment.

Recent Findings

Significant clinical and radiographic effects were observed in animal and human study models. In recent studies, local usage of the bisphosphonate gels was examined in periodontitis patients to prevent the systemic side effects. The mean pocket depth reduction, clinical attachment level gain, and the percentage of defect depth reduction were greater in bisphosphonate group.


Bisphosphonates appear to be effective in improving clinical outcomes of periodontal treatment. However, the clinical relevance still remains controversial because of the differences in methodology in the studies. New evidences from high-quality clinical trials are required to clear the clinical application of bisphosphonates as adjunct to non-surgical periodontal treatment in periodontitis.


Periodontitis Bisphosphonates Non-surgical periodontal therapy 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol. 1999;4(1):1–6. The classification of the periodontal diseases. Scholar
  2. 2.
    Page RC, Offenbacher S, Schroeder HE, et al. Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. Periodontol. 1997;14(1):216–48. Scholar
  3. 3.
    Sun Y, Guo QM, Liu DL, Zhang MZ, Shu R. In vivo expression of Toll-like receptor 2, Toll-like receptor 4, CSF2 and LY64 in Chinese chronic periodontitis patients. Oral Dis. 2010;16(4):343–50. Scholar
  4. 4.
    de Paula EC, de Freitas PM, Esteves-Oliveira M, et al. Laser phototherapy in the treatment of periodontal disease. A review. Lasers Med Sci. 2010;25:781–92.CrossRefGoogle Scholar
  5. 5.
    Bender JS, Thang H, Glogauer M. Novel rinse assay for the quantification of oral neutrophils and the monitoring of chronic periodontal disease. J Periodontal Res. 2006;41(3):214–20. Scholar
  6. 6.
    Cobb CM. Non-surgical pocket therapy: mechanical. Ann Periodontol. 1996;1(1):443–90. Scholar
  7. 7.
    de Oliveira RR, Schwartz-Filho HO, Novaes AB Jr, Garlet GP, de Freitas Souza R, Taba M Jr, et al. Antimicrobial photodynamic therapy in the non-surgical treatment of aggressive periodontitis: cytokine profile in gingival crevicular fluid, preliminary results. J Periodontol. 2009;80(1):98–105. Scholar
  8. 8.
    Haffajee AD. Systemic antibiotics: to use or not to use in the treatment of periodontal infections: that is the question. J Clin Periodontol. 2006;33(5):359–61. Scholar
  9. 9.
    Darveau RP, Tanner A, Page RC. The microbial challenge in periodontitis. Periodontol. 1997;14(1):12–32. Scholar
  10. 10.
    Giannobile WV. Host-response therapeutics for periodontal diseases. J Periodontol. 2008;79(Suppl. 8):1592–600. Scholar
  11. 11.
    Salvi GE, Lang NP. Host response modulation in the management of periodontal diseases. J Clin Peridontol. 2005;32(Suppl. 6):108–29. Scholar
  12. 12.
    Tani-Ishii N, Minamida G, Saitoh D, Chieda K, Omuro H, Sugaya A, et al. Inhibitory effects of incadronate on the progression of rat experimental periodontitis by Porphyromonas gingivalis infection. J Periodontol. 2003;74(5):603–9. Scholar
  13. 13.
    Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19(6):733–59. Scholar
  14. 14.
    Cochran DL. Inflammation and bone loss in periodontal disease. J Periodontol. 2008;79(8):1569–76. Scholar
  15. 15.
    Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(12):2961–78.<2961::AID-CNCR12>3.0.CO;2-L.CrossRefPubMedGoogle Scholar
  16. 16.
    Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18(2):75–85. Scholar
  17. 17.
    Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol. 2000;18(6):1378–91.
  18. 18.
    Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150–7. Scholar
  19. 19.
    Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373–9. Scholar
  20. 20.
    Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21(22):4253–4. Scholar
  21. 21.
    Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527–34. Scholar
  22. 22.
    Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99–102.CrossRefPubMedGoogle Scholar
  23. 23.
    Melo MD, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc. 2005;71(2):111–3.PubMedGoogle Scholar
  24. 24.
    Vannucchi AM, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol. 2005;128(6):738. Scholar
  25. 25.
    •• Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–1117. First cases in avascular necrosis of the jaws. Scholar
  26. 26.
    Saia G, Blandamura S, Bettini G, Tronchet A, Totola A, Bedogni G, et al. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg. 2010;68(4):797–804. Scholar
  27. 27.
    Khosa AD, Nayyar MS, Beirne JC. Osteochemonecrosis of jaws and bisphosphonates. Ir Med J. 2007;100(3):410–1.PubMedGoogle Scholar
  28. 28.
    Killeen AC, Rakes PA, Schmid MJ, Reinhardt RA, et al. Impact of local and systemic alendronate on simvastatin-induced new bone around periodontal defects. J Periodontol. 2012;83:1463–71.CrossRefPubMedGoogle Scholar
  29. 29.
    Furlaneto FAC, Nunes NLT, Oliveira Filho IL, et al. Effects of locally administered tiludronic acid on experimental periodontitis in rats. J Periodontol. 2014;85:1291–301.CrossRefPubMedGoogle Scholar
  30. 30.
    Carmen L, Mueller S, Tatiana MD, et al. Effect of alendronate on the progression of periodontitis induced by Porphyromonas gingivalis and Fusobacterium nucleatum: a study in rats. Clin Oral Investig. 2016;20:2565–73.CrossRefGoogle Scholar
  31. 31.
    Oktay AS, Chukkapalli SS, Rivera-Kweh MF, et al. Periodontitis in rats induces systemic oxidative stress that is controlled by bone-targeted. J Periodontol. 2015;86(1):137–45. Scholar
  32. 32.
    Almeida J, Ervolino E, Bonfietti LH, et al. Adjuvant therapy with sodium alendronate for the treatment of experimental periodontitis in rats. J Periodontol. 2015;86(10):1166–75. Scholar
  33. 33.
    Buduneli E, Buduneli N, Vardar-Sengül S, Kardeşler L, Atilla G, Lappin D, et al. Systemic low-dose doxycycline and alendronate administration and serum interleukin-1 beta, osteocalcin, and C-reactive protein levels in rats. J Periodontol. 2005;76(11):1927–33. Scholar
  34. 34.
    Buduneli E, Vardar-Sengül S, Buduneli N, Atilla G, Wahlgren J, Sorsa T. Matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and laminin-5 gamma2 chain immunolocalization in gingival tissue of endotoxin-induced periodontitis in rats: effects of low-dose doxycycline and alendronate. J Periodontol. 2007;78(1):127–34. Scholar
  35. 35.
    Bhavsar NV, Trivedi SR, Dulani K, Brahmbhatt N, Shah S, Chaudhri D. Clinical and radiographic evaluation of effect of risedronate 5 mg as an adjunct to treatment of chronic periodontitis in postmenopausal women. Osteoporos Int. 2016;27(8):2611–9. Scholar
  36. 36.
    Grgić O, Kovačev-Zavišić B, Veljović T, Novaković-Paro J, Maravić T, Bajkin B. The influence of bone mineral density and bisphosphonate therapy on the determinants of oral health and changes on dental panoramic radiographs in postmenopausal women. Clin Oral Investig. 2017;21(1):151–7. Scholar
  37. 37.
    Palomo L, Buencamino-Francisco MCA, Carey JJ, Sivanandy M, Thacker H. Is long-term bisphosphonate therapy associated with benefits to the periodontium in postmenopausal women? Menopause. 2011;18(2):164–70. Scholar
  38. 38.
    Palomo L, Bissada NF, Liu J. Periodontal assessment of postmenopausal women receiving risedronate. Menopause. 2005;12(6):685–90. Scholar
  39. 39.
    Lane N, Armitage GC, Loomer P, Hsieh S, Majumdar S, Wang HY, et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol. 2005;76(7):1113–22. Scholar
  40. 40.
    Rocha ML, Malacara JM, Sanchez-Marin FJ, et al. Effect of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial. J Periodontol. 2004;75(12):1579–85. Scholar
  41. 41.
    Mostafa B, Hamdy E, Nasif N. Combined effect of systemic bisphosphonates, calcium and vitamin D on alveolar bone in osteoporotic postmenopausal females having chronic periodontitis following surgical periodontal therapy. Life Sci J. 2012;9:613–22.Google Scholar
  42. 42.
    Tanna NK, Jeffcoat MK. Actonel® (risedronate) therapy for the maintenance of alveolar bone in adult chronic periodontitis. Health. 2013;5(07):12–7. Scholar
  43. 43.
    Kochman RH, Kochman T, Stabholz A, et al. Bisphosphonate and estrogen replacement therapy in post-menopausal periodontitis. Isr Med Assoc J. 2004;6:173–7.PubMedGoogle Scholar
  44. 44.
    Rackoff P. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Clin Interv Aging. 2009;4:207–14.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Sharma A, Raman A, Pradeep AR. Role of 1% alendronate gel as adjunct to mechanical therapy in the treatment of chronic periodontitis among smokers. J Appl Oral Sci. 2017;25(3):243–9. Scholar
  46. 46.
    Dutra BC, Oliveira AMSD, Oliveira PAD, et al. Effect of 1% sodium alendronate in the non-surgical treatment of periodontal intraosseous defects: a 6-month clinical trial. J Appl Oral Sci. 2017;25(3):310–7. Scholar
  47. 47.
    • Pradeep AR, Kumari M, Rao NS, Naik SB. 1% alendronate gel as local drug delivery in the treatment of class II furcation defects: a randomized controlled clinical trial. J Periodontol. 2013;84(3):307–315. First study in the treatment of class II furcation defects with local bisphosphate gel. Scholar
  48. 48.
    • Sharma A, Pradeep AR. Clinical efficacy of 1% alendronate gel in adjunct to mechanotherapy in the treatment of aggressive periodontitis: a randomized controlled clinical trial. J Periodontol. 2012;83(1):19–26. First study in the treatment of aggressive periodontitis with local bisphosphate gel. Scholar
  49. 49.
    • Sharma A, Pradeep AR. Clinical efficacy of 1% alendronate gel as a local drug delivery system in the treatment of chronic periodontitis: a randomized, controlled clinical trial. J Periodontol. 2012;83(1):11–18. First study in the treatment of chronic periodontitis with local bisphosphate gel. Scholar
  50. 50.
    Pradeep AR, Sharma A, Rao NS, Bajaj P, Naik SB, Kumari M. Local drug delivery of alendronate gel for the treatment of patients with chronic periodontitis with diabetes mellitus: a double-masked controlled clinical trial. J Periodontol. 2012;83(10):1322–8. Scholar
  51. 51.
    Jeffcoat MK, Cizza G, Shih WJ, Genco R, Lombardi A. Efficacy bisphosphonates for the control of alveolar bone loss in periodontitis. J Int Acad Periodontol. 2007;9(3):70–6.PubMedGoogle Scholar
  52. 52.
    Pradeep AR, Kanoriya D, Singhal S, et al. Comparative evaluation of subgingivally delivered 1% alendronate versus 1.2% atorvastatin gel in treatment of chronic periodontitis: a randomized placebo-controlled clinical trial. J Investig Clin Dent. 2017;8(3):e12215.
  53. 53.
    Veena HR, Prasad D. Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects. J Indian Soc Periodontol. 2010;14(1):40–5. Scholar
  54. 54.
    Srisubut S, Teerakapong A, Vattraphodes T, et al. Effect of local delivery of alendronate on bone formation in bioactive glass grafting in rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:11–6. CrossRefGoogle Scholar
  55. 55.
    Välimäki VV, Moritz N, Yrjans JJ, Vuorio E, Aro HT. Effect of zoledronic acid on incorporation of a bioceramic bone graft substitute. Bone. 2006;38(3):432–43. Scholar
  56. 56.
    Rosenqvist K, Airaksinen S, Fraser SJ, Gordon KC, Juppo AM. Interaction of bioactive glass with clodronate. Int J Pharm. 2013;452(1-2):102–7. Scholar
  57. 57.
    Rosenqvist K, Airaksinen S, Vehkamäki M, Juppo AM. Evaluating optimal combination of clodronate and bioactive glass for dental application. Int J Pharm. 2014;468(1-2):112–20. Scholar
  58. 58.
    Abtahi J, Tengvall P, Aspenberg P. A bisphosphonate-coating improves the fixation of metal implants in human bone. A randomized trial of dental implants. Bone. 2012;50(5):1148–51. Scholar
  59. 59.
    Tengvall P, Skoglund B, Askendal A, Aspenberg P. Surface immobilized bisphosphonate improves stainless-steel screw fixation in rats. Biomaterials. 2004;25(11):2133–8. Scholar
  60. 60.
    Wermelin K, Aspenberg P, Linderback P, et al. Bisphosphonate coating on titanium screws increases mechanical fixation in rat tibia after two weeks. J Biomed Mater Res A. 2008;86(1):220–7. Scholar
  61. 61.
    Wermelin K, Suska F, Tengvall P, Thomsen P, Aspenberg P. Stainless steel screws coated with bisphosphonates gave stronger fixation and more surrounding bone. Histomorphometry in rats. Bone. 2008;42(2):365–71. Scholar
  62. 62.
    Abtahi J, Henefalk G, Aspenberg P. Randomised trial of bisphosphonate-coated dental implants: radiographic follow-up after five years of loading. Int J Oral Maxillofac Surg. 2016;45(12):1564–9. Scholar
  63. 63.
    Zuffetti F, Testori T, Capelli M, Rossi MC, del Fabbro M. The topical administration of bisphosphonates in implant surgery: a randomized split-mouth prospective study with a follow-up up to 5 years. Clin Implant Dent Relat Res. 2015;17:e168–76. Scholar
  64. 64.
    Hiltunen AK, Skogman ME, Rosenqvist K et al. Bioactive glass combined with bisphosphonates provides protection against biofilms formed by the periodontal pathogen Aggregatibacter actinomycetemcomitans Int J Pharm. 2016;501:211–20.
  65. 65.
    Reshamwala SM, Mamidipally C, Pissurlenkar RR, et al. Evaluation of use of risedronate as an antibiofilm agent. J Med Microbiol. 2016;65(1):9–18. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.School of Dentistry, Department of PeriodontologyEge UniversityIzmirTurkey

Personalised recommendations